| Date | Title | Description |
| 18.06.2026 | Rejoni Secures $25M for Uterine Health Innovation, Juveena System Nears Launch | Rejoni, a leading women's health company, secured $25 million. This substantial financing fuels the advanced development and market introduction of its Juveena Hydrogel System. Juveena aims to revolutionize uterine healing. It targets the r... |
| 16.06.2026 | Rejoni Secures $25 Million To Advance Juveena Hydrogel System Toward FDA Approval And Commercial Launch | Rejoni, a clinical-stage women’s health company focused on biomaterial therapies, announced the closing of a $25 million financing round to support the development and commercialization of the Juveena Hydrogel System.
The financing included... |
| 16.06.2026 | Rejoni Raises $25M in Funding | Rejoni, Inc., a Bedford, MA-based clinical-stage company which specializes in uterine health, raised $25M in funding.
Backers included Clavyst Bio, Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventur... |
| 28.04.2026 | Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer | SINGAPORE, PARIS and PHILADELPHIA, April 28, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company developing novel therapies for patients suffering from life-threatening cardiomyopathies, today announced the appointment of ... |
| 18.10.2025 | Leyden Labs Secures €30M for Groundbreaking Respiratory Nasal Spray | Leyden Laboratories, a Dutch biotechnology pioneer, recently secured a significant €30 million in equity funding. The European Innovation Council (EIC) Fund and Invest-NL spearheaded this investment. This crucial capital injection will prop... |
| 17.10.2025 | Leyden Labs: €30 Million Secured From EIC And Invest-NL | Dutch biotechnology company Leyden Laboratories B.V. has secured €30 million in new equity financing from the European Innovation Council (EIC) Fund and Invest-NL. The investment will accelerate the clinical development of the company’s pan... |
| 02.10.2025 | Cirrus Therapeutics Raises $11M in Seed Financing | Cirrus Therapeutics, a Cambridge, MA-based ocular immunology-focused biotech company, closed an $11m seed financing.
The round was led by ClavystBio, with participation from Polaris Partners and SEEDS.
The company will use the financing to ... |
| 21.08.2025 | SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM | Now in its fourth year, the programme continues to empower biotech startups through ecosystem support and collaboration to advance science that serves patients.
SINGAPORE, Aug. 21, 2025 /PRNewswire/ -- Singzyme, a Singapore-based biotech st... |
| 24.07.2025 | Deals in brief: Respiree raises Series A funding, HeyMax expands with Krip acquisition, latest China deals, and more | Respiree raises Series A funding to scale health monitoring AI
Respiree, a health tech company founded in Singapore, has raised USD 11.6 million in a Series A funding round co-led by We Venture Capital and ClavystBio. Other participants inc... |
| 24.07.2025 | ClavystBio co-anchors $11.6m funding in healthtech Respiree | - |
| 10.06.2025 | ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore | SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have sign... |
| 28.05.2025 | To develop novel therapies for cardiomyopathy, Nuevocor raised $45 M Series B funding | The Singapore-based IND-stage biotechnology startup Nuevocor, which is working to find treatments for cardiomyopathies caused by aberrant mechanobiology, has successfully closed a $45 million Series B funding round.
Nuevocor said in a state... |
| 07.05.2025 | Nuevocor's $45 Million Leap: A New Dawn for Cardiomyopathy Treatment | In the world of biotechnology, every dollar counts. A recent infusion of $45 million into Nuevocor, a Singapore-based company, is more than just a financial boost. It’s a lifeline for patients grappling with cardiomyopathies, particularly t... |
| 06.05.2025 | Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy | – Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund
– Proceeds will support the Phase 1/2 clinical trial of le... |
| 22.10.2024 | Sunbird Bio: $14 Million Closed To Advance Blood-Based Diagnostic Platform In Alzheimer’s Disease | Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve the diagnosis and treatment of neurological disorders and early-stage cancer, announced the closing of a $14 million financing round backed by t... |
| 15.08.2024 | NSG BioLabs and Merck Collaborates to Support Biotech Start-ups to Advance Research & Innovations | The collaboration focuses on offering guidance, mentorship, and access to expertise to the start-ups housed within NSG Biolabs
SINGAPORE, Aug. 15, 2024 /PRNewswire/ -- NSG BioLabs, Singapore's largest provider of biotech co-working laborato... |
| 12.06.2024 | NSG BioLabs and Eppendorf Group Sign Partnership to Support Biotech Companies in Singapore | Since 2019, NSG BioLabs has been a leader in co-working lab spaces in Singapore, and has nurtured over 40 biotech companies, of which the startups have achieved nearly US$400 million funding in total alongside significant business milestone... |
| 12.05.2024 | NSG BioLabs: A Catalyst for Biotech Innovation in Singapore and Southeast Asia | NSG BioLabs, a pioneer in co-working lab spaces in Singapore, has been a driving force in nurturing over 40 biotech companies since 2019. These startups have collectively secured nearly US$400 million in funding and achieved significant bus... |
| 08.05.2024 | NSG BioLabs Fuels Biotech Innovation in Singapore and Southeast Asia Through Partnerships with EnterpriseSG and Merck, Alongside Investments from Celadon Partners and ClavystBio | Since 2019, NSG BioLabs has been a leader in co-working lab spaces in Singapore, and has nurtured over 40 biotech companies, of which the startups have achieved nearly US$400 million funding in total alongside significant business milestone... |
| 07.05.2024 | Singapore co-working laboratory provider NSG BioLabs raises $14.5m | NSG BioLabs, a Singapore-based provider of biotech co-working laboratories and office spaces, has raised $14.5 million in a financing round led by private equity firm Celadon Partners, and ClavystBio, a life sciences investor and venture bu... |
| 15.09.2022 | ClavystBio launches to translate life sciences breakthroughs into health impact | ClavystBio will invest and work with partners to accelerate life sciences commercialisation in Singapore through three pillars: collaborate, venture and build.
ClavystBio has committed US$220 million to date in investments to launch global ... |
